Harry Dolstra

8.0k total citations · 2 hit papers
123 papers, 5.2k citations indexed

About

Harry Dolstra is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Harry Dolstra has authored 123 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Immunology, 64 papers in Oncology and 50 papers in Hematology. Recurrent topics in Harry Dolstra's work include Immune Cell Function and Interaction (69 papers), CAR-T cell therapy research (52 papers) and Immunotherapy and Immune Responses (45 papers). Harry Dolstra is often cited by papers focused on Immune Cell Function and Interaction (69 papers), CAR-T cell therapy research (52 papers) and Immunotherapy and Immune Responses (45 papers). Harry Dolstra collaborates with scholars based in Netherlands, United States and Germany. Harry Dolstra's co-authors include Nicolaas Schaap, Willemijn Hobo, Robbert van der Voort, Frank Preijers, Hanny Fredrix, Frans Maas, Joop H. Jansen, Anniek B. van der Waart, Theo M. de Witte and Théo de Witte and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Harry Dolstra

122 papers receiving 5.1k citations

Hit Papers

Hematopoietic cell transplantation and cellular therapy s... 2021 2026 2022 2024 2021 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
    2021 223 citations Jakob Passweg, Helen Baldomero et al. Bone Marrow Transplantation profile →
  2. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
    2022 159 citations John A. Snowden, Isabel Sánchez‐Ortega et al. Bone Marrow Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harry Dolstra Netherlands 42 3.3k 2.4k 1.6k 1.1k 291 123 5.2k
Justin Kline United States 33 3.6k 1.1× 2.8k 1.2× 938 0.6× 1.2k 1.1× 383 1.3× 146 5.5k
Lawrence G. Lum United States 39 2.2k 0.6× 1.9k 0.8× 971 0.6× 1.0k 0.9× 334 1.1× 212 4.7k
Djordje Atanackovic Germany 43 2.1k 0.6× 2.1k 0.9× 1.2k 0.7× 1.6k 1.5× 182 0.6× 142 4.4k
Daniel H. Fowler United States 33 2.2k 0.7× 1.2k 0.5× 1.5k 0.9× 737 0.7× 392 1.3× 140 4.2k
Thomas Valerius Germany 42 3.0k 0.9× 1.9k 0.8× 760 0.5× 1.9k 1.8× 493 1.7× 145 5.5k
Sophie Paczesny United States 41 3.1k 0.9× 965 0.4× 2.9k 1.8× 903 0.8× 618 2.1× 159 5.5k
Joseph W. Fay United States 43 3.7k 1.1× 2.3k 1.0× 1.7k 1.1× 1.7k 1.6× 472 1.6× 105 6.3k
Sarah Nikiforow United States 31 1.4k 0.4× 1.8k 0.7× 1.2k 0.7× 463 0.4× 354 1.2× 152 3.4k
Sherif S. Farag United States 30 2.0k 0.6× 1.3k 0.5× 1.8k 1.1× 877 0.8× 594 2.0× 137 4.2k
Stephan Mielke Germany 31 1.6k 0.5× 1.9k 0.8× 1.7k 1.0× 688 0.6× 257 0.9× 110 3.7k

Countries citing papers authored by Harry Dolstra

Since Specialization
Citations

This map shows the geographic impact of Harry Dolstra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Dolstra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Dolstra more than expected).

Fields of papers citing papers by Harry Dolstra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Dolstra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Dolstra. The network helps show where Harry Dolstra may publish in the future.

Co-authorship network of co-authors of Harry Dolstra

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Dolstra. A scholar is included among the top collaborators of Harry Dolstra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Dolstra. Harry Dolstra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Passweg, Jakob, Helen Baldomero, Fabio Ciceri, et al.. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation. 58(6). 647–658. 35 indexed citations
3.
Yakoub‐Agha, Ibrahim, Raffaella Greco, Francesco Onida, et al.. (2023). Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplantation. 58(6). 696–700. 10 indexed citations
4.
Bulder, Ingrid, Carlijn Kuijk, Marion Kleijer, et al.. (2023). Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer. Cytotherapy. 26(2). 136–144. 2 indexed citations
5.
Brummelman, Jolanda, Dorette S. van Ingen Schenau, Mirjam H.M. Heemskerk, et al.. (2023). Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo. Cellular and Molecular Life Sciences. 80(10). 298–298. 2 indexed citations
6.
Waart, Anniek B. van der, Willemijn Hobo, Jianming Wu, et al.. (2023). Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity. Cytotherapy. 26(3). 252–260. 6 indexed citations
7.
Passweg, Jakob, Helen Baldomero, Christian Chabannon, et al.. (2022). Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation. 57(5). 742–752. 41 indexed citations
8.
Snowden, John A., Isabel Sánchez‐Ortega, Selim Corbacioglu, et al.. (2022). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation. 57(8). 1217–1239. 159 indexed citations breakdown →
9.
Passweg, Jakob, Helen Baldomero, Christian Chabannon, et al.. (2021). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation. 56(7). 1651–1664. 223 indexed citations breakdown →
10.
Weigelin, Bettina, Annemieke Th. den Boer, Esther Wagena, et al.. (2021). Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. Nature Communications. 12(1). 5217–5217. 146 indexed citations
11.
Thordardottir, Soley, Anniek B. van der Waart, J.H. Frederik Falkenburg, et al.. (2021). Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer Immunology Immunotherapy. 70(11). 3167–3181. 16 indexed citations
12.
Evert, Janneke S. Hoogstad‐van, Alan J. Korman, Paul K.J.D. de Jonge, et al.. (2020). TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. OncoImmunology. 9(1). 1843247–1843247. 54 indexed citations
13.
Hobo, Willemijn, et al.. (2020). Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer Immunology Immunotherapy. 69(11). 2259–2273. 3 indexed citations
14.
Guldevall, Karolin, Paul K.J.D. de Jonge, Janneke S. Hoogstad‐van Evert, et al.. (2020). IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer Immunology Immunotherapy. 70(5). 1305–1321. 33 indexed citations
15.
Waart, Anniek B. van der, Diana Campillo-Davó, Hanny Fredrix, et al.. (2020). PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. Bone Marrow Transplantation. 55(12). 2308–2318. 15 indexed citations
16.
Hobo, Willemijn, et al.. (2019). Comprehensive Phenotyping of T Cells Using Flow Cytometry. Cytometry Part A. 95(6). 647–654. 137 indexed citations
17.
Heskamp, Sandra, Janneke D.M. Molkenboer‐Kuenen, Soley Thordardottir, et al.. (2018). PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. Cancer Immunology Research. 7(1). 150–161. 30 indexed citations
18.
Hobo, Willemijn, Yun Ji, Hanny Fredrix, et al.. (2018). Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. OncoImmunology. 7(10). e1488565–e1488565. 45 indexed citations
19.
Thordardottir, Soley, Hanny Fredrix, Rob Woestenenk, et al.. (2016). CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. The Journal of Immunology. 197(7). 2715–2725. 40 indexed citations
20.
Norde, Wieger J., Frans Maas, Willemijn Hobo, et al.. (2011). PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation. Cancer Research. 71(15). 5111–5122. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Justin Kline Breakdown of academic impact, for papers by Lawrence G. Lum Breakdown of academic impact, for papers by Djordje Atanackovic Breakdown of academic impact, for papers by Daniel H. Fowler Breakdown of academic impact, for papers by Thomas Valerius Breakdown of academic impact, for papers by Sophie Paczesny Breakdown of academic impact, for papers by Joseph W. Fay Breakdown of academic impact, for papers by Sarah Nikiforow Breakdown of academic impact, for papers by Sherif S. Farag Breakdown of academic impact, for papers by Stephan Mielke
Rankless by CCL
2026